

PLXND1 Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Reactivity: H	Sensitivity: Endogenous	MW (kDa): 250	Source/Isotype: Rabbit	UniProt ID: #Q9Y4D7	Entrez-Gene Id: 23129
	Application Western Blotting			Dilution 1:1000	
	Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
sitivity	PLXND1 Antibody recognizes endogenous levels of total PLXND1 protein.				
	Rat				
cation	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val1665 of human PLXND1 protein. Antibodies are purified by protein A and peptide affinity chromatography.				
	PLXND1 (PlexinD1) is a type I transmembrane receptor for semaphorin (SEMA) family signaling molecules (1). PLXND1 has an extracellular SEMA binding domain, and a cytoplasmic tail containing RasGAP motifs and a RhoGTPase-binding domain. Upon ligand binding, PLXND1 undergoes conformational change and acquires GAP activity that inactivates downstream Rac/Ras signaling, leading to focal adhesion destabilization (2). The PLXND1 signaling pathway plays important roles in neuronal synapse formation, vascular branching, and thymocyte migration (2-4). Increased expression of PLXND1 is positively correlated with tumor stages in multiple cancer types (6). This is supported by gene knockdown experiments that suggest that SEMA/PLXND1 signaling may contribute metastatic progression (7-8).				
eferences	1. Gu, C. and Giraudo, E. (2013) <i>Exp Cell Res</i> 319, 1306-16. 2. Gay, C.M. et al. (2011) <i>Dev Biol</i> 349, 1-19. 3. Pecho-Vrieseling, E. et al. (2009) <i>Nature</i> 459, 842-6. 4. Zygmunt, T. et al. (2011) <i>Dev Cell</i> 21, 301-14. 5. Choi, Y.I. et al. (2008) <i>Immunity</i> 29, 888-98. 6. Rehman, M. et al. (2016) <i>PLoS One</i> 11, e0164660. 7. Tseng, C.H. et al. (2011) <i>PLoS One</i> 6, e19396. 8. Casazza, A. et al. (2010) <i>J Clin Invest</i> 120, 2684-98.				
		Application Western Blotting Supplied in 10 mM so 20°C. Do not aliquot to sitivity PLXND1 Antibody records are residues surrounding peptide affinity chrom PLXND1 (PlexinD1) is molecules (1). PLXND1 RasGAP motifs and a conformational change leading to focal adhes neuronal synapse for of PLXND1 is positivel gene knockdown experior progression (7-8). Peferences 1. Gu, C. and Giraudo, 2. Gay, C.M. et al. (2013. Pecho-Vrieseling, E. 4. Zygmunt, T. et al. (2006. Rehman, M. et al. (2007. Tseng, C.H. et al. (2006. Rehman, M. et al. (2006. Rehman,	Application Western Blotting Supplied in 10 mM sodium HEPES (pH 7.5 20°C. Do not aliquot the antibody. Sitivity PLXND1 Antibody recognizes endogenous residues surrounding Val1665 of human peptide affinity chromatography. PLXND1 (PlexinD1) is a type I transmemb molecules (1). PLXND1 has an extracellula RasGAP motifs and a RhoGTPase-binding conformational change and acquires GAI leading to focal adhesion destabilization neuronal synapse formation, vascular bra of PLXND1 is positively correlated with tu gene knockdown experiments that sugge progression (7-8). Peferences 1. Gu, C. and Giraudo, E. (2013) Exp Cell Face 2. Gay, C.M. et al. (2011) Dev Biol 349, 1-1 3. Pecho-Vrieseling, E. et al. (2009) Natural 4. Zygmunt, T. et al. (2011) Dev Cell 21, 30 5. Choi, Y.I. et al. (2008) Immunity 29, 888 6. Rehman, M. et al. (2016) PLoS One 11, 7. Tseng, C.H. et al. (2011) PLoS One 6, e1	Application Western Blotting Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg 20°C. Do not aliquot the antibody. PLXND1 Antibody recognizes endogenous levels of total PLXND1 Rat Sequence Polyclonal antibodies are produced by immunizing animals with residues surrounding Val1665 of human PLXND1 protein. Antibo peptide affinity chromatography. PLXND1 (PlexinD1) is a type I transmembrane receptor for semal molecules (1). PLXND1 has an extracellular SEMA binding domain RasGAP motifs and a RhoGTPase-binding domain. Upon ligand be conformational change and acquires GAP activity that inactivates leading to focal adhesion destabilization (2). The PLXND1 signalin neuronal synapse formation, vascular branching, and thymocyte of PLXND1 is positively correlated with tumor stages in multiple gene knockdown experiments that suggest that SEMA/PLXND1 sprogression (7-8). 2ferences 1. Gu, C. and Giraudo, E. (2013) Exp Cell Res 319, 1306-16. 2. Gay, C.M. et al. (2011) Dev Biol 349, 1-19. 3. Pecho-Vrieseling, E. et al. (2009) Nature 459, 842-6. 4. Zygmunt, T. et al. (2011) Dev Cell 21, 301-14. 5. Choi, Y.I. et al. (2008) Immunity 29, 888-98. 6. Rehman, M. et al. (2016) PLoS One 11, e0164660. 7. Tseng, C.H. et al. (2011) PLoS One 6, e19396.	Application Western Blotting Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% gl 20°C. Do not aliquot the antibody. PLXND1 Antibody recognizes endogenous levels of total PLXND1 protein. Rat Polyclonal antibodies are produced by immunizing animals with a synthetic peptide residues surrounding Val1665 of human PLXND1 protein. Antibodies are purified by peptide affinity chromatography. PLXND1 (PlexinD1) is a type I transmembrane receptor for semaphorin (SEMA) famil molecules (1). PLXND1 has an extracellular SEMA binding domain, and a cytoplasmic RasGAP motifs and a RhoGTPase-binding domain. Upon ligand binding, PLXND1 unconformational change and acquires GAP activity that inactivates downstream Rac/F leading to focal adhesion destabilization (2). The PLXND1 signaling pathway plays in neuronal synapse formation, vascular branching, and thymocyte migration (2-4). Incof PLXND1 is positively correlated with tumor stages in multiple cancer types (6). Thi gene knockdown experiments that suggest that SEMA/PLXND1 signaling may contriprogression (7-8). 1. Gu, C. and Giraudo, E. (2013) Exp Cell Res 319, 1306-16. 2. Gay, C.M. et al. (2011) Dev Biol 349, 1-19. 3. Pecho-Vrieseling, E. et al. (2009) Nature 459, 842-6. 4. Zygmunt, T. et al. (2011) Dev Cell 21, 301-14. 5. Choi, V.I. et al. (2008) Immunity 29, 888-98. 6. Rehman, M. et al. (2011) PLoS One 6, e19396.

Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X

Applications Key W: Western Blotting

Cross-Reactivity Key H: Human

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for a constant of their respective owners and the property of their respective owners.

 $more\ information.$

Limited UsesExcept as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's

terms and conditions that are in addition to, or different from, those contained herein, unless

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.